Aurinia Pharmaceuticals Inc. (AUPH) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary highlights strong financial performance, including significant revenue growth, improved margins, and a notable increase in net income. The company also announced a share repurchase program, which is generally viewed favorably by investors. Despite management's reluctance to provide specific guidance on certain R&D projects, the overall sentiment from the earnings call is positive, supported by raised guidance and improved financial health. The Q&A section did not reveal any major concerns that would significantly offset the positive financial results and strategic initiatives.
Key Financial Performance
Total Revenue (3 months ended June 30, 2025) $70 million, up 22% year-over-year from $57.2 million in the same period of 2024. The increase is attributed to strong growth in net product sales and further market penetration of LUPKYNIS.
Total Revenue (6 months ended June 30, 2025) $132.5 million, up 23% year-over-year from $107.5 million in the same period of 2024. The increase is attributed to strong growth in net product sales and further market penetration of LUPKYNIS.
Net Product Sales of LUPKYNIS (3 months ended June 30, 2025) $66.6 million, up 21% year-over-year from $55 million in the same period of 2024. The increase is primarily due to an increase in the number of LUPKYNIS cartons sold to specialty pharmacies, driven by further LN market penetration.
Net Product Sales of LUPKYNIS (6 months ended June 30, 2025) $126.5 million, up 23% year-over-year from $103.1 million in the same period of 2024. The increase is primarily due to an increase in the number of LUPKYNIS cartons sold to specialty pharmacies, driven by further LN market penetration.
Cash Flow Generated from Operations (6 months ended June 30, 2025) $45.5 million, compared to a negative $2.8 million in the same period of 2024. Excluding $11.5 million in cash payments made in connection with the November 2024 restructuring, cash flow generated from operations was $57 million. The improvement is attributed to operational efficiency and restructuring efforts.
Cash, Cash Equivalents, Restricted Cash, and Investments (as of June 30, 2025) $315.1 million, compared to $358.5 million as of December 31, 2024. The decrease is due to share repurchases and other operational expenditures.
Cost of Revenue (3 months ended June 30, 2025) $7.1 million, compared to $8.9 million in the same period of 2024. The decrease is primarily due to a reduction in sales of LUPKYNIS inventory to Otsuka, which has a lower gross margin.
Cost of Revenue (6 months ended June 30, 2025) $15.7 million, compared to $16.7 million in the same period of 2024. The decrease is primarily due to a reduction in sales of LUPKYNIS inventory to Otsuka, which has a lower gross margin.
Gross Margin (3 months ended June 30, 2025) 90%, compared to 84% in the same period of 2024. The improvement is due to a favorable sales mix.
Gross Margin (6 months ended June 30, 2025) 88%, compared to 85% in the same period of 2024. The improvement is due to a favorable sales mix.
Total Operating Expenses (3 months ended June 30, 2025) $49.9 million, compared to $58.7 million in the same period of 2024. The decrease is primarily due to lower personnel expenses, including share-based compensation and overhead costs, as a result of strategic restructuring efforts in 2024.
Total Operating Expenses (6 months ended June 30, 2025) $90.5 million, compared to $122.3 million in the same period of 2024. The decrease is primarily due to lower personnel expenses, including share-based compensation and overhead costs, as a result of strategic restructuring efforts in 2024.
Net Income (3 months ended June 30, 2025) $21.5 million or $0.16 earnings per share, compared to $722,000 or $0.01 earnings per share in the same period of 2024. The increase is attributed to higher revenue and improved operational efficiency.
Net Income (6 months ended June 30, 2025) $44.9 million or $0.33 earnings per share, compared to a net loss of $10 million or $0.07 net loss per share in the same period of 2024. The improvement is attributed to higher revenue and improved operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
LUPKYNIS net product sales: Net product sales of LUPKYNIS, the first FDA-approved oral therapy for active lupus nephritis, were $66.6 million and $126.5 million for Q2 and the first half of 2025, respectively, reflecting a 21% and 23% increase from the same periods in 2024. Growth was driven by increased market penetration.
Aritinercept Phase I results: Positive results were reported from the aritinercept Phase I single ascending dose study. Aritinercept is a dual BAFF APRIL inhibitor with potential applications in at least two autoimmune diseases. Further clinical studies are planned for the second half of 2025.
Market penetration of LUPKYNIS: Increased market penetration of LUPKYNIS contributed to higher sales, indicating a stronger foothold in the lupus nephritis treatment market.
Revenue growth: Total revenue for Q2 and the first half of 2025 was $70 million and $132.5 million, up 22% and 23% from the same periods in 2024.
Cash flow improvement: Cash flow generated from operations was $45.5 million for the first half of 2025, compared to a negative $2.8 million in the same period of 2024. Excluding restructuring-related payments, cash flow was $57 million.
Gross margin improvement: Gross margin improved to 90% for Q2 2025 and 88% for the first half of 2025, compared to 84% and 85% in the same periods of 2024.
Operating expense reduction: Total operating expenses decreased to $49.9 million and $90.5 million for Q2 and the first half of 2025, respectively, due to lower personnel and overhead costs following 2024 restructuring.
Share repurchase program: The company repurchased $11.2 million of its common shares in the first half of 2025 and increased the share repurchase plan authorization by an additional $150 million.
Revenue guidance increase: Full-year 2025 total revenue guidance was raised to $260-$270 million, and net product sales guidance was increased to $250-$260 million, reflecting confidence in sustained growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company acknowledges significant risks and uncertainties related to forward-looking statements, which could materially affect financial results and business operations. This includes potential regulatory hurdles and compliance issues.
Market Penetration Challenges: While LUPKYNIS sales have increased, the company faces challenges in further penetrating the LN market, which could impact future revenue growth.
Supply Chain and Cost Management: The decrease in cost of revenue is partly due to lower sales of LUPKYNIS inventory to Otsuka, which has a lower gross margin. This indicates potential vulnerabilities in supply chain and cost management strategies.
Strategic Execution Risks: The company is advancing development activities for aritinercept and voclosporin, but these initiatives involve increased R&D expenses and uncertainties in clinical development outcomes.
Economic and Financial Risks: The company has reduced cash reserves from $358.5 million to $315.1 million as of June 30, 2025, and is heavily reliant on cash flows from operations to fund share repurchases and other activities. This could pose financial risks if operational cash flows decline.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company has increased its full-year 2025 total revenue guidance from a range of $250 million to $260 million to a range of $260 million to $270 million.
Net Product Sales Guidance: Net product sales guidance has been raised from a range of $240 million to $250 million to a range of $250 million to $260 million.
Clinical Development Plans: The company plans to initiate further clinical studies for aritinercept in at least two autoimmune diseases in the second half of 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Plan: The company repurchased $11.2 million of its common shares for $90.8 million, including commissions and excise tax, for the 6 months ended June 30, 2025. Since the launch of the program in the first quarter of 2024 through today, the company repurchased 18.3 million of its common shares for $138.4 million, excluding commissions and excise tax. Additionally, the Board has approved an increase to the share repurchase plan of up to an additional $150 million of common shares over the initially approved $150 million Board authorization.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you guide us through the potential for aritinercept and its development strategy?
A:The company sees potential in B-cell mediated diseases and APRIL/BAFS's ability to address them. They have identified over 20 B-cell-mediated diseases for potential exploration. However, they are not disclosing specific approaches or indications for competitive reasons. They are confident in a Q4-week dosing schedule based on single ascending dose study data.
Q:What effects are being seen from the updated ACR guidelines on LUPKYNIS adoption?
A:The updated ACR guidelines have led to an increase in rheumatology prescribers and hospital business. Rheumatologists are adopting the drug at a faster rate than nephrologists, and teaching institutions are using the guidelines more proactively. However, the response lacked quantitative data.
Q:What are the drivers behind the raised guidance for LUPKYNIS?
A:The raised guidance is based on historical trends and current business growth. The lower to mid-range of guidance assumes a summer slowdown with growth resuming later, while the higher range assumes continued growth through Q3 and Q4. The company is encouraged by current business metrics.
Q:When can we expect the next data update for the MAD phase of aritinercept, and what are the factors influencing the choice of disease settings?
A:The company plans to enroll studies for at least two B-cell-mediated diseases by the end of the year but is not disclosing specific timing or disease settings for competitive reasons. They are moving forward with their strategy but are keeping details confidential.
Q:What is the status of formulation work for AUR200, and what is its purpose?
A:The formulation work for AUR200 is ongoing and aims to develop a patient-friendly formulation, potentially including an auto-injector. This work is being done in parallel with development efforts.
Q:How should we think about R&D spending and cash flow during the development of AUR200?
A:The company has not provided specific guidance on R&D expenses or cash flow. They emphasize efficient operations and cash flow management as priorities.
Q:Will the SAD study data for AUR200 be presented at a medical conference?
A:The company intends to present the SAD study data at an upcoming medical conference but has not determined which one yet.
Q:Under what circumstances will the company disclose details about the indications for AUR200?
A:Details will be disclosed when the development reaches a phase where it becomes public information, such as clinicaltrials.gov listings. The company is withholding information for competitive reasons.
Q:Are there any updates on Paragraph IV filers and exclusivity for LUPKYNIS?
A:There are no changes regarding Paragraph IV filers or exclusivity. The worst-case scenario for exclusivity is July 2028, not including pediatric exclusivity. The company continues to prioritize defending its intellectual property.
Q:How will the company balance R&D spending and share buybacks in the future?
A:The company emphasizes its strong cash flow from LUPKYNIS and its ability to fund R&D while potentially continuing share buybacks. Decisions on buybacks are at the Board's discretion and depend on cash flow and operational priorities.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers or sufficient details on several topics, including the specific indications for aritinercept, the timing of data updates, and the exact impact of updated ACR guidelines on LUPKYNIS adoption. They also did not provide quantitative guidance on R&D spending or cash flow during AUR200 development.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Aritinercept BAFF
BAFF track
BCMA domain
CEO today
Co LLC
Commission today
Cowen Research
Devroe Soghikian
Director Douglas
LLC Research
Miller Chief
Research Division
aritinercept
cash payment
commission excise
connection restructuring
cost
decrease period
excise tax
flow cash
flow month
flow period
liability
month income
month share
payment connection
period month
plan share
product sale
repurchase plan
restructuring cash
result update
sale month
share commission
share period
AUPH Transcript
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call shows strong financial performance with significant revenue growth, increased cash flow, and substantial net income improvements. Positive factors include raised guidance, successful LUPKYNIS sales, and a substantial share repurchase plan. Despite some concerns in the Q&A about unclear management responses and terminated studies, overall sentiment remains positive due to strong financial metrics and optimistic future guidance.
Aurinia Pharmaceuticals Inc. (AUPH) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call reveals strong financial performance with significant revenue and EPS growth. The company raised its revenue guidance and demonstrated confidence in continued growth, especially with LUPKYNIS. Although there were some uncertainties regarding FDA requests, the overall sentiment remains positive due to the raised guidance and strong financial metrics. The Q&A section reinforced positive trends and growth potential, contributing to a positive stock price prediction.
Aurinia Pharmaceuticals Inc. (AUPH) Q2 2025 Earnings Call Transcript
Positive7-31
The earnings call summary highlights strong financial performance, including significant revenue growth, improved margins, and a notable increase in net income. The company also announced a share repurchase program, which is generally viewed favorably by investors. Despite management's reluctance to provide specific guidance on certain R&D projects, the overall sentiment from the earnings call is positive, supported by raised guidance and improved financial health. The Q&A section did not reveal any major concerns that would significantly offset the positive financial results and strategic initiatives.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2025 Earnings Call Transcript
Positive5-13
The earnings call presents a strong financial performance with a 24% revenue increase and a transition to net income, alongside a robust gross margin. The share repurchase program indicates confidence in the stock. Despite potential challenges like supply chain issues and patent litigation, the optimistic guidance and strategic focus on growth drivers are positive. The Q&A highlights management's proactive approach to market dynamics, suggesting stability and potential growth. Given these factors, the stock is likely to see a positive movement, with a potential increase of 2% to 8% over the next two weeks.
AUPH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
